55 th. Catanzaro. Annual Meeting of the Italian Cancer Society September : understanding onc-omics for patient-tailored cancer therapy

Transcription

1 In collaboration with

2 CONGRESS VENUE Università degli Studi Magna Græcia di Viale Europa Germaneto - Villaggio Guglielmo Congress Center Piazza Susanna, Copanello - ORGANIZING SECRETARIAT Adria Congrex Srl Via Sassonia, Rimini RN Ph Fax sic2013@adriacongrex.it Web site SIC SECRETARIAT Società Italiana di Cancerologia Via G. Venezian, Milan Ph Fax sic@istitutotumori.mi.it Web site

3 Welcome Address Dear Members of SIC, Colleagues and Friends, It is our great pleasure to welcome you in for the 55th (SIC). The title of the 2013 meeting is Welcome to the South - Understanding Onc OMICS for Patient Tailored Cancer Therapy. This title echoes a popular series of movies and underlines the fact that this conference is the first SIC Meeting to be held in Calabria. In addition to its wealth of natural beauty and of history, this Region hosts one of the youngest and most dynamic Universities in Italy, the University Magna Græcia of, strongly commitment to bio-medical research and in particular to translational cancer research. The recently-established University Campus S. Venuta, where the inaugural session will be held, is a modern, residential campus equipped with state-of-art facilities for cell biology, functional genomics and proteomics, bio-computing and drug design, and for pre-clinical studies in animal models of disease. The 2013 Meeting will be focused on highly relevant and timely topics including Non-coding RNAs, Cancer Biochemistry and Metabolism, Cancer Genomics and Epigenomics, Cancer Stem Cells, Animal Modelling of Cancer, Advanced Diagnostics and Therapeutics. The basic goal of this meeting is to highlight how world-wide efforts to catalogue mutations in multiple cancer types are underway and discuss whether and how this may lead to novel discoveries that will be translated into new diagnostic tools, prognostic indicators and therapeutic targets. There will be plenary lectures and presentations from top Italian and international experts in the field of cancer, together with those given by young scientists, and focused breakthrough sessions particularly dedicated to a comprehensive update on the most recent laboratory and clinical developments in the field of cancer. Traditional SIC events will be the Giorgio Prodi memorial lecture, and the joint session with the Italian Association of Medical Oncology (AIOM), to highlight the connection between basic research and new therapeutic approaches. The opening lecture will be held by Daniel Peeper, and the closing lecture by John Quackenbush. Our Society continues to encourage the young investigators with initiatives aimed at improving their professional growth and qualification. In this respect, the Meeting will dedicate to young scientists four poster discussion sessions focusing on highly relevant topics, the Piero Trivella and EACR Prizes for the best posters, the Elena Cappannini Award for the best publication, the Pezcoller Foundation scholarship, as well as travel grants and formative credits. We thank you for your participation, and hope that this Meeting will be most enjoyable and productive for everybody. Giuseppe Viglietto Scientific Coordinator Riccardo Dolcetti SIC President 1

4 WITH THE AUSPICES OF University of Magna Graecia Centro interdipartimentale di genomica e patologia molecolare Fondazione per la Ricerca e la Cura dei Tumori Tommaso Campanella 2

5 Committee SIC SCIENTIFIC BOARD President Riccardo Dolcetti (CRO-IRCCS, National Cancer Institute, Aviano, Pordenone, Italy) President Elect Silvia Giordano (Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy) Board Anna Bagnato (Regina Elena National Cancer Institute, Rome, Italy) Vincenzo Bronte (University of Verona, Italy) Maurizio D Incalci ( Mario Negri Institute for Pharmacological Research, Milan, Italy) Nicola Normanno (National Cancer Institute G. Pascale, Naples, Italy) Salvatore Pece (IFOM-IEO Campus, University of Milan, Italy) Katia Scotlandi (IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy) Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy) Stefania Tommasi (National Cancer Centre Giovanni Paolo II, Bari, Italy) Giuseppe Viglietto (University Magna Græcia,, Italy) Past President Alfredo Fusco ( Federico II University, Naples, Italy) Representative for Young Researchers Chiara Gabellini (Regina Elena National Cancer Institute, Rome, Italy) Pierlorenzo Pallante (Institute of Endocrinology and Experimental Oncology, CNR, Naples, Italy) SCIENTIFIC AND ORGANIZING COMMITTEE Scientific Coordinator Giuseppe Viglietto (University Magna Græcia,, Italy) Local Scientific Committee Gennaro Ciliberto (National Cancer Institute G. Pascale, Naples, Italy; University Magna Græcia,, Italy) Francesco Saverio Costanzo (University Magna Graecia,, Italy) Gianni Cuda (University Magna Græcia,, Italy) Dolores Di Vizio (Cedars Sinai Medical Center, Los Angeles, CA, USA) Marcello Maggiolini (University of Cosenza, Italy) Giovanni Morrone (University Magna Græcia,, Italy) Pierosandro Tagliaferri (University Magna Græcia,, Italy) Pierfrancesco Tassone (University Magna Græcia,, Italy) 3

6 Faculty Valter Agosti University Magna Græcia,, Italy Paolo Ascierto National Cancer Institute G. Pascale, Naples, Italy Anna Bagnato Regina Elena National Cancer Institute, Rome, Italy Rosa Bernardi IRCCS San Raffaele Hospital, Milan, Italy Renzo Canetta Bristol-Myers Squibb, Wallingford, CT, USA Ugo Cavallaro European Institute of Oncology, Milan, Italy Paola Chiarugi University of Florence, Italy Gennaro Ciliberto National Cancer Institute G. Pascale, Naples, Italy; University Magna Græcia,, Italy Pierpaolo Correale University of Siena, Italy Giovanni Cuda University Magna Græcia,, Italy Donatella Del Bufalo Regina Elena National Cancer Institute, Rome, Italy Francesca Demichelis University of Trento, Italy Simona De Summa National Cancer Centre Giovanni Paolo II, Bari, Italy Maurizio D Incalci Mario Negri Institute for Pharmacological Research, Milan, Italy Federica Di Nicolantonio Institute for Cancer Research and Treatment, Candiolo, Turin, Italy Dolores Di Vizio Cedars Sinai Medical Center, Los Angeles, CA, USA Riccardo Dolcetti CRO-IRCCS, National Cancer Institute, Aviano, Pordenone, Italy Giulio Draetta MD Anderson Cancer Center, Houston, TX, USA Manuela Ferracin University of Ferrara, Italy Riccardo Fodde Josephine Nefkens Institute Erasmus University Medical Centre, Rotterdam, The Netherlands Niels Frandsen Exiqon, Vedbaek, Denmark Guido Franzoso Imperial College, London, United Kingdom Alfredo Fusco Federico II University, Naples, Italy Cecilia Garofalo IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy Silvia Giordano Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy Eric Holland Memorial Sloan Kettering Cancer Center, New York, NY, USA Antonio Iavarone Columbia University, New York, NY, USA Jeffrey J. Legos GlaxoSmithKline, Collegeville, PA, USA Marco Macagno University of Turin, Italy Norman J. Maitland University of York, United Kingdom Maria Caterina Mione Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany Andrea Morandi University of Florence, Italy Giovanni Morrone University Magna Græcia,, Italy Nicola Normanno National Cancer Institute G. Pascale, Naples, Italy Giorgio Parmiani IRCCS San Raffaele Hospital, Milan, Italy Daniel Peeper The Netherlands Cancer Institute, Amsterdam, The Netherlands John Quackenbush Dana-Farber Cancer Institute, Boston, MA, USA Lucia Ricci Vitiani ISS, Istituto Superiore di Sanità, Rome, Italy Mercedes Robledo Spanish National Cancer Centre (CNIO), Madrid, Spain Mark A. Rubin Weill Cornel Medical College, New York, NY, USA Massimo Santoro Federico II University, Naples, Italy Aldo Scarpa University of Verona, Italy Jan J. Schuringa Faculty of Medical Sciences, Hematology, Groningen, The Netherlands Katia Scotlandi IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy Salvatore Siena Niguarda Ca Granda Hospital, Milan, Italy Frank J. Slack Yale University, New Haven, CT, USA Gabriella Sozzi IRCCS National Cancer Institute, Milan, Italy Henk J. Stunnenberg Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands Pierosandro Tagliaferri University Magna Græcia,, Italy Pierfrancesco Tassone University Magna Græcia,, Italy Stefania Tommasi National Cancer Centre Giovanni Paolo II, Bari, Italy Giancarlo Vecchio Federico II University, Naples, Italy Giuseppe Viglietto University Magna Græcia,, Italy Stefano Volinia University of Ferrara, Italy 4

7 Programme at a glance Monday, September 23th - University of 1300 Registration Opening ceremony Opening lecture NON CODING RNAS CANCER BIOCHEMISTRY AND METABOLISM Welcome cocktail Tuesday, September 24th - Villaggio Guglielmo 0730 Registration Meet the expert informal round table@breakfast CANCER GENOMICS AND EPIGENOMICS Coffee break ADVANCED OMIC TECHNOLOGIES IN CANCER RESEARCH Lunch Poster viewing with the presence of Authors ADVANCED DIAGNOSTICS AND THERAPEUTICS Coffee break Meeting of the SIC young investigators Wednesday, September 25th - Villaggio Guglielmo Meet the expert informal round table@breakfast Poster Discussion 1A - 1B Coffee break Giorgio Prodi lecture Poster viewing with the presence of Authors Lunch Poster Discussion 2A - 2B CANCER STEM CELLS AWARD CEREMONY SIC General Assembly Social Dinner Thursday, September 26th - Villaggio Guglielmo ANIMAL MODELS OF CANCER Coffee break Closing lecture Award for the best oral selected presentation Closing remarks Lunch 5

8 13.00 Registration OPENING CEREMONY Monday 23 September SCIENTIFIC PROGRAMME Ve n u e Un i v e r s i t y o f Ca t a n z a r o, Au d i t o r i u m GREETINGS FROM THE AUTHORITIES A. Quattrone (Magnifico Rettore Magna Graecia University,, Italy) R. Dolcetti (SIC President, Aviano PN, Italy) GREETINGS FROM EACR D. Del Bufalo (EACR Executive Committee Member, Regina Elena National Cancer Institute, Rome, Italy) OPENING LECTURE Chair R. Dolcetti (Aviano PN, Italy) Function-based screening for therapeutic targets in cancer D. Peeper (Amsterdam, The Netherlands) Sponsored by EACR NON CODING RNAS Chairmen S. Giordano (Turin, Italy) - P. Tassone (, Italy) MicroRNAs as targeted therapeutics and therapeutic targets in cancer F.J. Slack (New Haven, USA) MicroRNA and lung cancer G. Sozzi (Milan, Italy) Role of MicroRNAs in progression and invasiveness of breast cancer S. Volinia (Ferrara, Italy) The role of mirnas in regulating angiogenesis C25 in BRCA related breast cancer K. Danza (IRCCS-National Cancer Center Giovanni Paolo II,Bari, Italy), S. De Summa, B. Pilato, R. Lacalamita, O. Popescu, R. Lambo, M. Carella, S. Tommasi mirna landscape in Stage I Epithelial Ovarian Cancer C29 defines the histotype specificities L. Paracchini (Mario Negri Institute for Pharmacological Research, Milan, Italy), E. Calura, L. Zanotti, R. Fruscio, M. Di Marino, L. Beltrame., R. Baldo R., S. Magni, A. Ravaggi, E. Bignotti, G. Tognon, E. Sartori, S. Pecorelli, D. Katsaros, M. D Incalci, C. Romualdi, S. Marchini 6

9 Monday 23 September SCIENTIFIC PROGRAMME Ve n u e Un i v e r s i t y o f Ca t a n z a r o, Au d i t o r i u m CANCER BIOCHEMISTRY AND METABOLISM Chairmen G. Cuda (, Italy) - G. Vecchio (Naples, Italy) Cancer-selected targeting of the NF-ĸB pathway G. Franzoso (London, UK) Reciprocal metabolic deregulation of tumors and their stroma P. Chiarugi (Florence, Italy) Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune F2 C-terminal interaction M. Carotenuto, P. De Antonellis, L. Liguori, D. Spano, A. M. Bello, V. Ferrucci, A. Alonzi, D. Magliulo, C. M. Chiarolla, S. Di Somma, N. Aiese, M. Zollo (CEINGE, Naples, Italy) The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting G7 succinate dehydrogenase A. Rasola (University of Padua, Italy) Welcome Cocktail Shuttle Bus from the University to Villaggio Gugliemo 7

10 7.30 Registration Tuesday 24 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o MEET THE EXPERT INFORMAL ROUND TABLE@BREAKFAST Parallel Sessions An i ma l Mo d e l s E. Holland (New York, USA) - M. Mione (Eggenstein-Leopoldshafen, Germany) Ca n c e r Stem Cells N. Maitland (York, United Kingdom) - R. Fodde (Rotterdam, The Netherlands) CANCER GENOMICS AND EPIGENOMICS Chairmen K. Scotlandi (Bologna, Italy) - S. Tommasi (Bari, Italy) The drivers of oncogenesis and master regulators of glioblastoma A. Iavarone (New York, USA) Next generation histopathological diagnosis from genomics to clinical application A. Scarpa (Verona, Italy) From OMIC to the patient M. Robledo (Madrid, Spain) Coffee Break Molecular archeology from next generation explorations F. Demichelis (Trento, Italy) Detection of genetic and epigenetic alterations in plasma circulating tumor DNA F. Di Nicolantonio (Turin, Italy) A massive parallel sequencing approach in a selected hereditary C19 breast/ovarian cancer serie highlights ATM as an important breast cancer predisposing A. Buffone, A. Coppa (Sapienza University of Rome, Italy), S. Casadei, A. Prodosmo, V. Colicchia, A. Nicolussi, S. D Inzeo, S. Brizi, S. Soddu, G. Giannini Estrogen receptor BETA/AGO2 complex binds to breast cancer cell genome H20 and mediates transcriptional gene regulation by the nuclear receptor R. Tarallo (University of Salerno, Baronissi,Italy), G. Nassa, G. Giurato, G. Bruno, A. Salvati, L. Ricciardi T. Rocco, F. Rizzo, A. Weisz 8

11 Tuesday 24 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o ADVANCED OMIC TECHNOLOGIES IN CANCER RESEARCH Chairmen G. Viglietto (, Italy) - G. Cuda (, Italy) Lunch How to implement therapeutic drug monitoring through mass spectrometry in oncology B. Casetta (AbSciex) Somatic variant screening in solid tumors with ion torrent semiconductor sequencing R. Tanzi (Life Technologies) Illumina solutions for cancer analysis N. Cirenei (Product Marketing Manager Europa Illumina) Initiatives in translational cancer research in Calabria brief presentation of the PON- and POR-funded projects A. Lidonnici (Biomedpark HEMMAS) POSTER VIEWING WITH THE PRESENCE OF THE AUTHORS ADVANCED DIAGNOSTICS AND THERAPEUTICS THE PHARMA S VIEW Chairmen G. Ciliberto (Naples, Italy) - M. D Incalci (Milan, Italy) LNA antisense oligonucleotides promising drug development platform and antisense tools for the study of RNA function in animals N. Frandsen (Exiqon, Vedbaek, Denmark) Challenges of drug discovery and development in the era of precision medicine J.J. Legos (GSK, Collegeville, USA) Immuno-oncology as a new modality of cancer treatment research and development R. Canetta (BMS, Wallingford, USA) Coffee Break THE CLINICIANS VIEW Joint Meeting SIC-AIOM Chairmen N. Normanno (Naples, Italy) - P. Tagliaferri (, Italy) Targeted drugs for melanoma P. Ascierto (Naples, Italy) Targeted drugs for colon carcinoma S. Siena (Milan, Italy) Combined immuno and chemotherapy/targeted therapy strategies G. Parmiani (Milan, Italy) Sponsored by EACR Colon cancer chemoimmunotherapy from bench to bedside P. Correale (Siena, Italy) MEETING OF SIC YOUNG INVESTIGATORS 9

12 Wednesday 25 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o MEET THE EXPERT INFORMAL ROUND TABLE@BREAKFAST Parallel Sessions Cancer Genomics A. Iavarone (New York, USA) - M.A. Rubin (New York, USA) Non Coding RNAs F.J. Slack (New Haven, USA ) Oncometabolics P. Chiarugi (Florence, Italy) POSTER DISCUSSION 1 Parallel Sessions Poster Discussion 1A Sala Cassiodoro CANCER genetics, epigenetics and control of gene expression Chairmen S. De Summa (Bari, Italy) - G. Viglietto (, Italy) E5 Critical role of zinc finger protein 521 in the control of growth and tumourigenicity of human medulloblastoma cells R. Spina, G. Filocamo, E. Iaccino, S. Scicchitano (University of Magna Graecia,, Italy), M. Lupia, E. Chiarella, T. Mega,F. Bernaudo, D. Pelaggi, M. Mesuraca, S. Pazzaglia, S. Semenkow, E.E. Bar, M. Kool,S. Pfister, H.M. Bond, C.G. Eberhart, C. Steinkuhler, G. Morrone E17 CXCR4 inhibition impairs stemness features and blocks the metastatic dissemination induced by chemotherapy of migrating lung cancer initiating cells G. Bertolini (IRCCS National Cancer Institute, Milan, Italy), M. Moro, M. Tortoreto, D. Wong, L. Gatti, R. Caserini, U. Pastorino, L. Roz,G. Sozzi C20 ATM protein kinase promotes HER2-dependent tumorigenesis V. Stagni (IRCCS-Fondazione Santa Lucia, Rome, Italy), V. Oropallo, M. Antonelli, R. Falcioni, A. Di Benedetto, M. Mottolese, D. Barila C23 SEMA6A and MICAL-1 sustain cell growth and survival of BRAF mutant human melanoma R. Loria, V. Perrotti, G. Bon, P. Baldassarri, I. Bersani, S. Rossi, R. Mortarini, A. Anichini, R. Falcioni (National Cancer Institute Regina Elena, Rome, Italy) H17 Histone deacetilase inhibitors repress the expression of the pro-invasive factor Runx2, in tumor cells, through a new intronic enhancer region V. Sancisi, G. Gandolfi, G. Damia, D. Ambrosetti, A. Ciarrocchi (Arcispedale S. Maria Nuova-IRCCS; Reggio Emilia, Italy) H4 MEF2 is a converging hub for HDAC4 and PI3K/Akt-induced transformation E. Di Giorgio (University of Udine, Italy), A. Clocchiatti, A. Sgorbissa, E. Gagliostro, C. Brancolini H3 Study of ADAR2 editing enzyme in astrocytoma proliferation A. Gallo (Ospedale Pediatrico Bambino Gesù IRCCS, Rome Italy), S. Tomaselli, F. Galeano, F. Locatelli E16 ERK5-inhibition as a novel approach to target CML stem cells E. Rovida (University of Florence, Italy), I. Tusa, G. Cheloni, N.S. Gray, X. Deng, P. Dello Sbarba 10

13 Wednesday 25 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o H21 Silencing of the collagen prolyl hydroxylases is associated with metastatic breast cancer and metastatic melanoma C. Lo Nigro (S. Croce General Hospital, Cuneo, Italy), H. Wang, L. Lattanzio, M. Monteverde, N. Syed, O. Garrone, M. Occelli, E. Hatzimichael, M. Merlano, C. Proby, A. Thompson, T. Crook Poster Discussion 1B Sala Ibico tumor immunology and microenvironment Chairmen A. Bagnato (Rome, Italy) - M. Macagno (Turin, Italy) U3 Effects induced by mir-29b on Multiple Myeloma (MM)-related immunological microenvironment C. Botta (University of Magna Graecia,, Italy), M. Rossi, M. R. Pitari, T. Del Giudice, A. Gullà, E. Morelli, L. Biamonte, N. Amodio, M. T. Di Martino, M. Ventura, P. Correale, P. Tagliaferri, P. Tassone U4 Exploiting immunogenic cancer cell death to improve dendritic cell-based immunotherapy J. Dal Col (CRO-IRCCS, Aviano PN; Italy), D. Martorelli, B. Montico, K. Mastorci, E. Comaro, R. Dolcetti B2 Role of senescent stroma in prostate cancer progression M. L. Taddei (University of Florence, Italy), G. Comito, L. Cavallini, E. Giannoni, P. Chiarugi F20 L-proline induces a mesenchymal like invasive program in embryonic stem cells by remodelling H3K9 and H3K36 methylation S. Comes, M. Gagliardi, N. Laprano, A. Fico, A. Cimmino, A. Palamidessi, C. Angelini, S. De Falco, G. Scita, E.J. Patriarca, M. R. Matarazzo, G. Minchiotti (Institute of Genetics and Biophysics A. Buzzati-Traverso, CNR, Naples, Italy) F6 F9 F3 CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce the incidence of tumor spreading and improve overall survival in preclinical models of prostate cancer G. L. Gravina, M. Tortoreto, A. Mancini, P. Muzi, L. Ventura, A. Addis, Y. Landesman, D. McCauley, M. Kauffman, S. Shacham, N. Zaffaroni, C. Festuccia (University of L Aquila, Italy) Acidic microenvironment drives melanoma progression through cell to cell sustained exosome-mediated transfer of metastatic molecules Z. Boussadia (Istituto Superiore di Sanità, Rome, Italy), I. Parolini, F. Felicetti, C. Coscia, S. Camerini, C. Zanetti, A. De Feo, L. Pasquini, M. Biffoni, A. Carè, M. Sargiacomo Characterization of transgenic mouse model and derivative cells line of SCLC induced by HPV-16 E6/E7 R. Martinelli (University of Salerno, Baronissi, Italy), S.L. Nori, F. De Caro, G. Boccia, M. Capunzo 11

14 Wednesday 25 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o U11 Development of human bispecific antibodies against CD20/CD55 and CD20/59 for the treatment of B-cell disorders P. Macor (University of Trieste, Italy), E. Secco, N. Mezzaroba, S. Zorzet, P. Durigutto, T. Gaiotto, F. Ziller, L. De Maso, S. Biffi, S. Capolla, M. Calvaruso, C. Tripodo, C. Garrivo, V. Gattei, R. Marzari, F. Tedesco, D. Sblattero V8 Gelatinases promote progression and metastasis in leiomyosarcoma in vitro and in vivo C. Alias, A. D Angelo (Azienda Ospedaliero-Universitaria, Parma, Italy), L. Rocchi, S. Caraffi, R. Perris, D. Mangieri Coffee Break GIORGIO PRODI LECTURE Introduction R. Dolcetti (Aviano PN, Italy) From RET oncogene identification in thyroid cancer to targeted therapy M. Santoro (Naples, Italy) POSTER VIEWING WITH THE PRESENCE OF AUTHORS Lunch POSTER DISCUSSION 2 Parallel Sessions Poster Discussion 2A Sala Cassiodoro drug resistance, signal transduction, targeted therapy Chairmen V. Agosti (, Italy) C. Garofalo (Bologna, Italy) L4 L2 Activation of the MET receptor drives resistance to anti EGFR therapies in colorectal cancer M. Apicella (University of Turin, Italy), S. Corso, A. Bertotti, S. Hobor, E. Bonazzina, A. Sartore-Bianchi, S. Siena, L. Trusolino, A. Bardelli, S. Giordano Role of Hedgehog pathway in mediating resistance to anti EGFR TKIs in NSCLC F. M. Morgillo, C.D. Della Corte (Second University of Naples, Italy), F.P. Papaccio, D.V. Vitagliano, F.C. Ciardiello T12 Taxanes enhanced trastuzumab-mediated ADCC of tumor cells through NKG2D mediated NK cell recognition T. Triulzi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), L. Sfondrini, S. Varchetta, V. Regondi, M. Di Modica, P. Casalini, A. Balsari, G. Bianchi, G. Mariani, E. Tagliabue T21 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib R. Rosa (Federico II University of Naples), L. Formisano, C. D Amato, V. D Amato, L. Nappi, R. Marciano, L. Raimondo, C. Di Mauro, A. Petrone, A. Servetto, V. Damiano, S. De Placido, R. Bianco 12

15 Wednesday 25 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o T6 Histone deacetylase inhibition leads to enhanced sensitization to pemetrexed via induction of apoptosis and autophagy in non small cell lung tumor models M. Di Martile, (Regina Elena National Cancer Institute, Rome, Italy), D. Trisciuoglio, M. Desideri, C. Gabellini, T. De Luca, A. Eramo, R. De Maria, M. Milella, D. Del Bufalo T10 Anti-tumor activity of a mir-199 dependent oncolytic adenovirus E. Callegari (University of Ferrara, Italy), B. K. Elamin,.L. D Abundo, M. Negrini, S. Sabbioni T5 Activation of an early feedback survival loop involving phospho-erbb3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-erbb3 antibodies L. Fattore (Sapienza University of Rome, Italy), E. Marra, M. E. Pisanu, A. Noto, C. De Vitis, F. Belleudi, L. Aurisicchio, R. Mancini, M. R. Torrisi, P. A. Ascierto, G. Ciliberto L7 Molecular Mechanism of Resistance to Afatinib in EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) cell lines and Potential Therapeutic Implications S. Coco (IRCCS, Azienda Ospedaliera Universitaria San Martino, Genoa, Italy), A. Truini, A. Alama, A. Garuti, E. Carminati, G. Barletta, M.G. Dal Bello, C. Genova, E. Rijavec, C. Sini, F. Grossi N16 Fenretinide (4-HPR) targets parental and cancer initiating medulloblastoma cells A. Pagani (University of Insubria Varese, Italy), D. Bartolini, A. Bruno, D.M. Noonan, A. Albini 13

16 Wednesday 25 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o Poster Discussion 2B Sala Ibico BIOMARKERS and therapy Chairmen D. Di Vizio (Los Angeles, USA) M. Ferracin (Ferrara, Italy) I3 I5 Functional connection between RAD51 and CCDC6 in homologous recombination directed repair in lung tumors new therapeutic perspectives? F. Morra (Institute of Endocrinology and Experimental Oncology, CNR, Naples, Italy), C. Luise, A. Marinelli, A. Milano, F. Merolla, A. Cerrato, A. Celetti PARP1 overexpression and mirna targeting DNA repair could they be biomarkers of the BRCAness phenotype? S. De Summa (National Cancer Centre Giovanni Paolo II, Bari, Italy), R. Pinto, B. Pilato, D. Petriella, K. Danza, E. Mattioli, D. Sambiasi, O. Palumbo, S. Tommasi P20 mir-205 and Trastuzumab potential as adjuvant therapeutic tool and predictive biomarker E. D Ippolito (Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy), I. Plantamura, M. Giussani, E. Liotti, L. Braccioli, P. Casalini, E. Tagliabue, M. V. Iorio S4 ImiR a reliable and accurate pipeline for analysis of small non coding RNA sequencing datastes G. Giurato (University of Salerno, Baronissi, Italy), A. Rinaldi, A. Hashim, M. R. De Filippo, D. Memoli, A. Weisz I4 The MRN complex is a potential target for the treatment of MYCN amplified Neuroblastoma M. Petroni, F. Sardina (Ospedale Bambino Gesù Rome, Italy), C. Heil, V. Veschi, S. Albini, D. Fruci, A. Gulino, G. Giannini P32 Class III β-tubulin is overexpressed in ovarian clear cell and serous carcinoma and represents a novel marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone E. Bignotti (University of Brescia, Italy), C. Romani, P. Todeschini, D.M. Roque, S. Bellone, R.A. Tassi, E. Bandiera, L. Zanotti, N. Buza, E. Cocco, T.J. Rutherford, P.E. Schwartz, A. Ravaggi, E. Sartori, A.D. Santin, S. Pecorelli P31 mirna signature characterization in round cell myxoid liposarcomas treated with trabectedin M. Di Marino (Mario Negri Institute of Milan, Italy), L. Beltrame, L. Paracchini, R. San Filippo, P. Casali, A. Gronchi, S. Pilotti, C. Romualdi, F. Bozzi, T. Negri, E. Calura, S. Marchini, M. D Incalci P36 MicroRNA-10b expression correlates with metastases development and survival in breast cancer patients R. Barbano, B. Pasculli, V.M. Valori, A. Fontana, M. Copetti, M.L. Poeta, G. Perrone, F. Pellegrini, A. Onetti-Muda, R. Murgo, E. Maiello, V.M. Fazio, P. Parrella (IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy) 14

17 Wednesday 25 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o P26 Evaluation of the prognosis role of IGF1R in prostate cancer patients and association with TMPRSS2-ERG status I. Casanova-Salas (Fundacion Instituto Valenciano de Oncologia, Valencia, Spain), C. Mancarella, J.A. López-Guerrero, K. Scotlandi CANCER STEM CELLS Chairmen A. Morandi (Florence, Italy) - G. Morrone (, Italy) The importance of asymmetry for gene expression in the stem cell compartment of human prostate epithelium N.J. Maitland (York, United Kingdom) Sponsored by EACR Stem cells in homeostasis and cancer the good, the bad and the ugly R. Fodde (Rotterdam, The Netherlands) Clinical implications of cancer stem cell hypothesis L. Ricci-Vitiani (Rome, Italy) Targeting pancreatic cancer stem cells G. Draetta (Houston, USA) Modeling of human leukemias J.J. Schuringa (Groningen, The Netherlands) Depletion of HIPK2 full-length protein preserving the ΔE8 isoform triggers E7 apoptosis in colon cancer stem cells in vitro and in vivo G. Di Rocco, V. Gatti, A. Verdina, M. Pietrafesa, G. Toietta, S. Soddu (National Cancer Institute Regina Elena, Rome, Italy) Radiotherapy induced mir expression influences the formation of local R7 recurrence in breast cancer L. Fabris (CRO National Cancer Institute, Aviano, Italy), S. Berton, S. Massarut, S. D Andrea, G. Calin, B. Belletti, G. Baldassarre AWARD CEREMONY SIC General Assembly Social Dinner 15

18 Thursday 26 September SCIENTIFIC PROGRAMME Ve n u e Vi l l a g g i o Gu g l i e l m o ANIMAL MODELS OF CANCER Chairmen R. Dolcetti (Aviano, PN, Italy) - A. Fusco (Naples, Italy) Mouse models of glioma subtypes E. Holland (New York, USA) The role of hypoxic responses in leukemogenesis R. Bernardi (Milan, Italy) Novel players in tumor microenvironment U. Cavallaro (Milan, Italy) Coffee Break Application of genomics to zebrafish models in cancer research M.A. Rubin (New York, USA) Zebrafish models of cancer M.C. Mione (Eggenstein-Leopoldshafen, Germany) AKT1-E17K is oncogenic in mouse and human lung through p27 delocalization A3 C. De Marco (University of Magna Graecia,, Italy) D. Malanga, O. Paciello, S. Papparella, F. Zito Marino, R. Franco, G. Viglietto Yes-associated protein is required for the clonal expansion of preneoplastic A6 hepatocytes and oval cell proliferation M.A. Kowalik (University of Cagliari, Italy), A. Perra, E. Ghiso, G.M. Ledda-Columbano, S. Giordano, A. Columbano Epigenomics functionally indexing genomes in health and disease H. Stunnenberg (Nijmegen, The Netherlands) CLOSING LECTURE Chair R. Dolcetti (Aviano PN, Italy) From Data to Knowledge Using omics to drive discovery J. Quackenbush (Boston, USA) AWARD FOR THE BEST ORAL SELECTED PRESENTATION CLOSING REMARKS Lunch 16

19 Scientific Information CME Credits No. 2,5 Italian Ministry of Health CME (Continuing Medical Education) credits for the event on September 23 and No 8 CME credits for the event from September 24 to 26 have been assigned for the following categories - Medical Surgeon (Haematology, Medical Genetics, Oncology, Pathological Anatomy, Pharmacology and Clinical Toxicology, Clinical Pathology, Internal Medicine) - Biologist, Pharmacist, Chemist (Analytical Chemistry), Physicist (Health Physics), Veterinary Surgeon AUDIOVISUAL INSTRUCTIONS A Multimedia Slide Centre is located in the Meeting Venue. ONLY PC DATA PROJECTION IS AVAILABLE DURING THE MEETING. Each room is provided with a laptop. Therefore the use of your personal laptop is not allowed. Special requirements should be communicated to the Organizing Secretariat as soon as possible. Power-Point presentations should be handed to the slide centre one hour before the beginning of the session. PRIZES Wednesday September 25 Piero Trivella and EACR Prizes to the best posters Elena Cappannini Prize to the best 2012 publication as first author in innovative approaches for cancer treatments Pezcoller Foundation Scholarship Travel Grants Thursday September 26 Award for the best oral selected presentation 17

20 General Information Dates, 23 26, September 2013 Congress Venue September 23 Università degli Studi Magna Græcia di Viale Europa Germaneto September Villaggio Guglielmo Congress Center Piazza Susanna, Copanello - SIC Secretariat Società Italiana di Cancerologia Via G. Venezian, Milan Ph Fax sic@istitutotumori.mi.it Web site Organizing Secretariat Adria Congrex Srl Via Sassonia, Rimini RN Ph Fax sic2013@adriacongrex.it Web site Language The official language of the Meeting is English. Simultaneous translation will not be provided. Badges Participants are kindly requested to wear their badge throughout the Meeting. Certificates of Attendance Certificate of attendance is issued on request to all registered participants at the end of the Meeting. Exhibition and Sponsorship A technical, pharmaceutical and publication exhibition will take place in the Meeting Venue throughout the scientific works. Additional sponsoring opportunities are available. For any information, please contact the Organizing Secretariat Adria Congrex. 18